Skip to content

Study · Randomized controlled trial · n = 39 · 2016

5 results

Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.

Ke W, Liu L, Liu J, Chen A, Deng W, Zhang P, Cao X, Liao Z, Xiao H, Liu J, Li Y

Journal of diabetes research10 Nov 2015Cited by 8 (Europe PMC)

PMID26640805 (opens in a new tab)PMCIDPMC4657099 (opens in a new tab)DOI10.1155/2016/6839735 (opens in a new tab)PepBankPUB-26640805
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

The objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model assessment (HOMA) indices, and acute insulin response (AIR) were compared between the two groups. The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P = 0.039). HbA1c at the end of study was comparable between two groups (6.3 ± 0.7% versus 6.0 ± 0.5%, for CSII alone group and CSII + Lira group, resp., P = 0.325). The increment of AIR was higher in CSII + Lira group (177.58 (351.57) μU · min/mL versus 58.15 (51.30) μU · min/mL, P < 0.001). However, after stopping liraglutide, its effect on beta cell function disappeared completely. Liraglutide combined with short-term CSII was effective in further improving beta cell function, but the beneficial effects did not sustain after suspension of the therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, CSII with liraglutide shortened the time to euglycemia compared with CSII alone (1 vs 2 days).

    In plain wordsIn adults with newly diagnosed type 2 diabetes, adding liraglutide to insulin pump therapy reached normal blood sugar sooner than the pump alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseTime to euglycemia
    Study

    n = 39

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Time to euglycemia
    1 days
    CSII + liraglutide
    Time to euglycemia
    2 days
    CSII alone

    Source sentences

    Summary
    The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P = 0.039).
    1 context sentence
    Summary · context
    Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the insulin dosage used to reach euglycemia was equivalent with CSII with liraglutide and with CSII alone.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, adding liraglutide did not change the insulin dose needed to reach normal blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin dosage needed to reach euglycemia
    Study

    n = 39

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P = 0.039).
    1 context sentence
    Summary · context
    Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, HbA1c at the end of the study was comparable between CSII with liraglutide and CSII alone.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, HbA1c at the end was similar with and without liraglutide added to insulin pump therapy.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c at end of study
    Study

    n = 39

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    HbA1c
    6.3%
    CSII alone
    HbA1c
    6%
    CSII + liraglutide

    Source sentences

    Summary
    HbA1c at the end of study was comparable between two groups (6.3 ± 0.7% versus 6.0 ± 0.5%, for CSII alone group and CSII + Lira group, resp., P = 0.325).
    1 context sentence
    Summary · context
    Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the increment of acute insulin response was higher with CSII with liraglutide than with CSII alone.

    In plain wordsIn newly diagnosed type 2 diabetes, adding liraglutide to insulin pump therapy gave a bigger rise in early insulin release than the pump alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseIncrement of acute insulin response (AIR)
    Study

    n = 39

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    AIR increment
    177.58 μU · min/mL
    CSII + liraglutide
    AIR increment
    58.15 μU · min/mL
    CSII alone

    Source sentences

    Summary
    The increment of AIR was higher in CSII + Lira group (177.58 (351.57) μU · min/mL versus 58.15 (51.30) μU · min/mL, P < 0.001).
    1 context sentence
    Summary · context
    Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the effect of liraglutide on beta cell function disappeared completely after liraglutide was stopped.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, the benefit of liraglutide on beta cell function was gone after the drug was stopped.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta cell function after stopping liraglutide
    Study

    n = 39

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    However, after stopping liraglutide, its effect on beta cell function disappeared completely.
    1 context sentence
    Summary · context
    Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.